Mika Komori

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 17

Top Topics

Clinical Evaluation

Top Venues

Neurology and therapy

Brain and behavior

Advances in therapy

Drugs - real world outcomes

This page only lists publications with an associated author ORCID identifier.

Publications

Takao Takeshima, Hikaru Doi, Satomi Ooba, Yuka Tanji, Akichika Ozeki, Mika Komori
Clinical Evaluation After Discontinuation of Galcanezumab in Japanese Patients with Episodic and Chronic Migraine: Analysis of a Randomized, Placebo-Controlled Trial and Open-label Extension Study. Neurology and therapy 13 (3) (2024)
Takao Takeshima, Hikaru Doi, Satomi Ooba, Yuka Tanji, Akichika Ozeki, Mika Komori
Clinical Evaluation After Discontinuation of Galcanezumab in Japanese Patients with Episodic and Chronic Migraine: Analysis of a Randomized, Placebo-Controlled Trial and Open-label Extension Study. Neurology and therapy 13 (3) (2024)
Hisaka Igarashi, Mika Komori, Kaname Ueda, Anthony J Zagar, Dena H Jaffe, Yasuhiko Matsumori, Takao Takeshima, Koichi Hirata
Underrecognition of migraine-related stigmatizing attitudes and social burden: Results of the OVERCOME Japan study. Brain and behavior 14 (7) (2024)
Etsuko Awaki, Takao Takeshima, Yasuhiko Matsumori, Koichi Hirata, Naoki Miyazaki, Ryo Takemura, Satoshi Osaga, Yoshinori Tanizawa, Mika Komori
Impact of Migraine on Daily Life: Results of the Observational survey of the Epidemiology, Treatment, and Care of Migraine (OVERCOME [Japan]) Study. Neurology and therapy 13 (1) (2024)
Etsuko Awaki, Takao Takeshima, Yasuhiko Matsumori, Koichi Hirata, Naoki Miyazaki, Ryo Takemura, Satoshi Osaga, Yoshinori Tanizawa, Mika Komori
Impact of Migraine on Daily Life: Results of the Observational survey of the Epidemiology, Treatment, and Care of Migraine (OVERCOME [Japan]) Study. Neurology and therapy 13 (1) (2024)
Takao Takeshima, Hikaru Doi, Satomi Ooba, Yuka Tanji, Akichika Ozeki, Mika Komori
Clinical Evaluation After Discontinuation of Galcanezumab in Japanese Patients with Episodic and Chronic Migraine: Analysis of a Randomized, Placebo-Controlled Trial and Open-label Extension Study. Neurology and therapy 13 (3) (2024)
Etsuko Awaki, Takao Takeshima, Yasuhiko Matsumori, Koichi Hirata, Naoki Miyazaki, Ryo Takemura, Satoshi Osaga, Yoshinori Tanizawa, Mika Komori
Impact of Migraine on Daily Life: Results of the Observational survey of the Epidemiology, Treatment, and Care of Migraine (OVERCOME [Japan]) Study. Neurology and therapy 13 (1) (2024)
Takao Takeshima, Hikaru Doi, Satomi Ooba, Yuka Tanji, Akichika Ozeki, Mika Komori
Clinical Evaluation After Discontinuation of Galcanezumab in Japanese Patients with Episodic and Chronic Migraine: Analysis of a Randomized, Placebo-Controlled Trial and Open-label Extension Study. Neurology and therapy (2024)
Hisaka Igarashi, Mika Komori, Kaname Ueda, Anthony J Zagar, Dena H Jaffe, Yasuhiko Matsumori, Takao Takeshima, Koichi Hirata
Underrecognition of migraine-related stigmatizing attitudes and social burden: Results of the OVERCOME Japan study. Brain and behavior 14 (7) (2024)
Etsuko Awaki, Takao Takeshima, Yasuhiko Matsumori, Koichi Hirata, Naoki Miyazaki, Ryo Takemura, Satoshi Osaga, Yoshinori Tanizawa, Mika Komori
Impact of Migraine on Daily Life: Results of the Observational survey of the Epidemiology, Treatment, and Care of Migraine (OVERCOME [Japan]) Study. Neurology and therapy (2024)
Etsuko Awaki, Takao Takeshima, Yasuhiko Matsumori, Koichi Hirata, Naoki Miyazaki, Ryo Takemura, Satoshi Osaga, Yoshinori Tanizawa, Mika Komori
Impact of Migraine on Daily Life: Results of the Observational survey of the Epidemiology, Treatment, and Care of Migraine (OVERCOME [Japan]) Study. Neurology and therapy 13 (1) (2024)
Takao Takeshima, Hikaru Doi, Satomi Ooba, Yuka Tanji, Akichika Ozeki, Mika Komori
Clinical Evaluation After Discontinuation of Galcanezumab in Japanese Patients with Episodic and Chronic Migraine: Analysis of a Randomized, Placebo-Controlled Trial and Open-label Extension Study. Neurology and therapy 13 (3) (2024)
Shigekazu Kitamura, Noboru Imai, Yuka Tanji, Akichika Ozeki, Mika Komori
Lasmiditan in Japanese Patients with Common Migraine Comorbidities or Concomitant Medications: A Post Hoc Safety and Efficacy Analysis from the MONONOFU Study. Journal of pain research 16 (2023)
Koichi Hirata, Mika Komori, Kaname Ueda, Anthony J Zagar, Yongin Kim, Dena H Jaffe, Yasuhiko Matsumori, Takao Takeshima
Outcomes and Factors Associated with Insufficient Effectiveness of Acute Treatments of Migraine in Japan: Results of the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) Study. Drugs - real world outcomes (2023)
Takao Takeshima, Kaname Ueda, Mika Komori, Anthony J Zagar, Yongin Kim, Dena H Jaffe, Yasuhiko Matsumori, Koichi Hirata
Potential Unmet Needs in Acute Treatment of Migraine in Japan: Results of the OVERCOME (Japan) Study. Advances in therapy 39 (11) (2022)
Takao Takeshima, Mika Komori, Yuka Tanji, Akichika Ozeki, Yoshihisa Tatsuoka
Efficacy of Lasmiditan Across Patient and Migraine Characteristics in Japanese Patients with Migraine: A Secondary Analysis of the MONONOFU Trial. Advances in therapy 39 (11) (2022)
Yasuhiko Matsumori, Mika Komori, Yuka Tanji, Akichika Ozeki, Fumihiko Sakai
Rapid Onset and Sustained Efficacy of Lasmiditan Among Japanese Patients with Migraine: Prespecified Analyses of a Randomized Controlled Trial. Neurology and therapy 11 (4) (2022)